Celldex’s Phase 1 Study of CDX-1401 Published in Science Translational Medicine

First clinical study to demonstrate that an off-the-shelf vaccine targeting dendritic cells can safely lead to robust humoral and cellular immunity April 16, 2014 Celldex Therapeutics, Inc. announced today that final data from its Phase 1 study of CDX-1401 in solid tumors, including long-term patient follow-up, have been published inĀ Science Translational MedicineĀ (Vol 6 Issue 232). The data demonstrate robust antibody …